IPO Update: Ideaya Biosciences Readies Terms For IPO

|
About: IDEAYA Biosciences, Inc. (IDYA)
by: Donovan Jones
This article is exclusive for subscribers.
Summary

IDEAYA Bio has filed proposed terms for its $70 million IPO.

With partner Novartis, the firm is developing a novel treatment for uveal melanoma with potential for a wider target set.

IDYA has an impressive investor list, strong collaboration with Novartis, and the IPO appears reasonably valued.

Quick Take

IDEAYA Biosciences (IDYA) intends to raise $70 million from the sale of its common stock in a U.S. IPO, per an amended registration statement.

The company is developing a pipeline